Exelixis (EXEL) Cash from Investing Activities Growth (1y) (2011 - 2026)
Exelixis (EXEL) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-114.28% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
826.39% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
- |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
-674.01% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Exelixis |
13.61 Bn |
12.83 Bn |
590.86 Mn |
-202.62% |
| Date | Value |
|---|
| Apr 3, 2026 |
-202.62% |
| Jan 2, 2026 |
129.23% |
| Oct 3, 2025 |
111.70% |
| Jul 4, 2025 |
203.32% |
| Apr 4, 2025 |
-55.49% |
| Jan 3, 2025 |
-250.96% |
| Sep 27, 2024 |
-726.05% |
| Jun 28, 2024 |
210.82% |
| Mar 29, 2024 |
325.43% |
| Dec 29, 2023 |
125.12% |
| Sep 29, 2023 |
150.30% |
| Jun 30, 2023 |
45.40% |
| Mar 31, 2023 |
33.47% |
| Dec 30, 2022 |
-1,782.67% |
| Sep 30, 2022 |
-224.64% |
| Jul 1, 2022 |
-90.76% |
| Apr 1, 2022 |
-219.73% |
| Dec 31, 2021 |
-104.01% |
| Apr 2, 2021 |
90.85% |
| Apr 3, 2020 |
130.30% |
